Enlivex Therapeutics Ltd. (TLV:ENLV)
Israel
· Delayed Price · Currency is ILS · Price in ILA 354.20
+29.60 (9.12%)
At close: Dec 4, 2025
Enlivex Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Cash & Equivalents | 4.08 | 3.3 | 0.81 | 49.95 | 11.2 | 5.67 | Upgrade
|
| Short-Term Investments | 14.12 | 20.2 | 26.51 | 0.3 | 72.93 | 30.03 | Upgrade
|
| Cash & Short-Term Investments | 18.2 | 23.5 | 27.32 | 50.24 | 84.13 | 35.71 | Upgrade
|
| Cash Growth | -25.72% | -14.00% | -45.63% | -40.28% | 135.61% | 197.36% | Upgrade
|
| Other Receivables | 0.76 | 1.42 | 0.23 | 0.65 | 1.2 | - | Upgrade
|
| Receivables | 0.76 | 1.42 | 0.23 | 0.65 | 1.2 | - | Upgrade
|
| Prepaid Expenses | 0.53 | 0.88 | 1.11 | 1.44 | 1.11 | 1.24 | Upgrade
|
| Restricted Cash | - | - | - | - | - | 1.17 | Upgrade
|
| Other Current Assets | 0.01 | 0.2 | 5.11 | - | - | - | Upgrade
|
| Total Current Assets | 19.5 | 25.99 | 33.76 | 52.33 | 86.44 | 38.12 | Upgrade
|
| Property, Plant & Equipment | 1.08 | 1.15 | 2.58 | 14.9 | 8.22 | 2.14 | Upgrade
|
| Other Long-Term Assets | 0.36 | 0.54 | 0.49 | 0.41 | 0.49 | 0.1 | Upgrade
|
| Total Assets | 20.94 | 27.69 | 36.83 | 67.64 | 95.15 | 40.36 | Upgrade
|
| Accounts Payable | 0.38 | 0.81 | 0.83 | 1.95 | 0.88 | 0.46 | Upgrade
|
| Accrued Expenses | 2.38 | 2.61 | 3.66 | 4.01 | 3.22 | 2.54 | Upgrade
|
| Current Portion of Leases | 0.28 | 0.24 | 0.35 | 0.65 | 0.62 | 0.2 | Upgrade
|
| Other Current Liabilities | - | 0.14 | 1.23 | - | - | 1.17 | Upgrade
|
| Total Current Liabilities | 3.03 | 3.8 | 6.06 | 6.61 | 4.72 | 4.37 | Upgrade
|
| Long-Term Leases | 0.43 | 0.3 | 0.69 | 4.19 | 5.39 | 0.5 | Upgrade
|
| Total Liabilities | 3.46 | 4.1 | 6.75 | 10.8 | 10.11 | 4.87 | Upgrade
|
| Common Stock | 2.76 | 2.69 | 2.14 | 2.12 | 2.11 | 1.65 | Upgrade
|
| Additional Paid-In Capital | 148.25 | 146.91 | 138.94 | 136.65 | 133.8 | 70.36 | Upgrade
|
| Retained Earnings | -134.63 | -127.11 | -112.09 | -83.03 | -51.97 | -37.5 | Upgrade
|
| Comprehensive Income & Other | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 0.98 | Upgrade
|
| Total Common Equity | 17.48 | 23.59 | 30.08 | 56.84 | 85.04 | 35.49 | Upgrade
|
| Shareholders' Equity | 17.48 | 23.59 | 30.08 | 56.84 | 85.04 | 35.49 | Upgrade
|
| Total Liabilities & Equity | 20.94 | 27.69 | 36.83 | 67.64 | 95.15 | 40.36 | Upgrade
|
| Total Debt | 0.7 | 0.53 | 1.03 | 4.85 | 6.01 | 0.7 | Upgrade
|
| Net Cash (Debt) | 17.5 | 22.96 | 26.29 | 45.4 | 78.12 | 35.01 | Upgrade
|
| Net Cash Growth | -26.28% | -12.65% | -42.09% | -41.89% | 123.18% | 202.11% | Upgrade
|
| Net Cash Per Share | 0.74 | 1.12 | 1.42 | 2.47 | 4.37 | 2.66 | Upgrade
|
| Filing Date Shares Outstanding | 24.29 | 23.65 | 18.6 | 18.42 | 18.37 | 18.31 | Upgrade
|
| Total Common Shares Outstanding | 24.29 | 23.65 | 18.6 | 18.42 | 18.33 | 14.59 | Upgrade
|
| Working Capital | 16.47 | 22.19 | 27.7 | 45.72 | 81.72 | 33.75 | Upgrade
|
| Book Value Per Share | 0.72 | 1.00 | 1.62 | 3.09 | 4.64 | 2.43 | Upgrade
|
| Tangible Book Value | 17.48 | 23.59 | 30.08 | 56.84 | 85.04 | 35.49 | Upgrade
|
| Tangible Book Value Per Share | 0.72 | 1.00 | 1.62 | 3.09 | 4.64 | 2.43 | Upgrade
|
| Machinery | 2.72 | 2.68 | 2.98 | 3.38 | 2.34 | 1.53 | Upgrade
|
| Leasehold Improvements | 0.95 | 0.95 | 1.43 | 8.61 | 1.52 | 0.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.